Pharma Pay for Delay Boosts Drug Profits at Consumer’s Expense

In a Los Angeles Times column, Michael Hiltzik descibes how Cephalon and other pharma companies pay generic drug makers to keep products off the market to enable them to stretch out  monopoly protection and the profits it brings. One analyst estimates on average a one-year delay in the entry of a generic version of a drug can cost consumers more than $660 million.